13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001346824
Total reported value
$11.5B
$11.5B
71 檔
41.4%
As reported in its official Q4 2025 Form 13F filing, Ra Capital Management, L.p.'s tracked investment portfolio stood at $11.5B with 71 total positions.
In Q4 2025, Ra Capital Management, L.p. displayed an active expansion posture, initiating 22 new positions and adding to 13 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ASND | Ascendis Pharma A/S | Stock-Other | 22.46% | -24.92% | EXIT | |
| 2 | CDTX | Cidara Therapeutics Inc | Stock-Other | 7.62% | — | — | |
| 3 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 7.31% | +0.29% | +17.35% | |
| 4 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 6.39% | — | — | |
| 5 | PCVX | Vaxcyte Inc | Stock-Other | 5.07% | -1.27% | -10.37% | |
| 6 | SION | Sionna Therapeutics Inc | Stock-Other | 4.17% | -0.42% | -5.17% | |
| 7 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 3.43% | -0.43% | -5.81% | |
| 8 | TYRA | Tyra Biosciences Inc | Stock-Other | 3.29% | -1.56% | — | |
| 9 | WVE | Wave Life Sciences Ltd. | Stock-Other | 3.17% | -0.71% | +0.01% | |
| 10 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 2.72% | -0.41% | — | |
| 11 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 2.65% | -0.52% | — | |
| 12 | SEPN | Septerna Inc | Stock-Other | 2.00% | +0.26% | — | |
| 13 | NUVL | Nuvalent Inc-a | Stock-Other | 1.94% | -1.41% | +50.83% | |
| 14 | IRON | Disc Medicine Inc | Stock-Other | 1.61% | -0.10% | +25.30% | |
| 15 | JANX | Janux Therapeutics Inc | Stock-Other | 1.58% | -0.16% | — | |
| 16 | PEPG | Pepgen Inc | Stock-Other | 1.34% | -0.07% | — | |
| 17 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 1.33% | +0.27% | — | |
| 18 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 1.30% | -0.16% | — | |
| 19 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 1.26% | -0.22% | — | |
| 20 | BCAX | Bicara Therapeutics Inc | Stock-Other | 1.20% | +0.34% | — | |
| 21 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.13% | -1.28% | EXIT | |
| 22 | GHRS | GH Research PLC | Stock-Other | 1.00% | +0.64% | — | |
| 23 | GERN | Geron CORP | Stock-Other | 0.86% | -0.53% | +5.62% | |
| 24 | ACLXGBX | Arcellx Inc | Stock-Other | 0.85% | — | -58.27% | |
| 25 | CLYM | Climb Bio Inc | Stock-Other | 0.80% | +0.46% | -64.05% | |
| 26 | VOR | Vor Biopharma Inc | Stock-Other | 0.72% | -0.64% | +172.66% | |
| 27 | BLTE | Belite Bio Inc - Adr | Stock-Other | 0.71% | — | -50.57% | |
| 28 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.70% | -0.49% | EXIT | |
| 29 | LENZ | Lenz Therapeutics Inc | Stock-Other | 0.68% | -0.20% | — | |
| 30 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.68% | -2.32% | EXIT | |
| 31 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 0.67% | -0.41% | EXIT | |
| 32 | EVMN | Evommune Inc | Stock-Other | 0.61% | -0.45% | — | |
| 33 | JBIO | Jade Biosciences Inc | Stock-Other | 0.58% | +0.16% | +245.57% | |
| 34 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.54% | -0.87% | EXIT | |
| 35 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.51% | -0.10% | — | |
| 36 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 0.50% | +0.04% | +24.29% | |
| 37 | MNPR | Monopar Therapeutics Inc | Stock-Other | 0.45% | +0.15% | +30.52% | |
| 38 | CAPR | Capricor Therapeutics Inc | Stock-Other | 0.45% | -0.17% | — | |
| 39 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.43% | +0.08% | +23.89% | |
| 40 | IVVD | Invivyd Inc | Stock-Other | 0.43% | — | — | |
| 41 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 0.43% | +0.84% | — | |
| 42 | GRAL | Grail Inc | Stock-Healthcare | 0.38% | -0.23% | EXIT | |
| 43 | ASMB | Assembly Biosciences Inc | Stock-Other | 0.36% | -0.06% | — | |
| 44 | SLDB | Solid Biosciences Inc | Stock-Other | 0.34% | +0.33% | — | |
| 45 | ABOS | Acumen Pharmaceuticals Inc | Stock-Other | 0.32% | -0.03% | — | |
| 46 | BNTC | Benitec Biopharma Inc | Stock-Other | 0.26% | +0.01% | — | |
| 47 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 0.26% | -0.18% | EXIT | |
| 48 | RZLT | Rezolute Inc | Stock-Other | 0.22% | +0.13% | — | |
| 49 | ACRV | Acrivon Therapeutics Inc | Stock-Other | 0.21% | +0.07% | — | |
| 50 | NKTX | Nkarta Inc | Stock-Other | 0.20% | +0.03% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CDTX | Cidara Therapeutics Inc | +3.7% | — | Unchanged |
| 2 | RNAGBP | Avidity Biosciences Inc | +1.8% | — | Unchanged |
| 3 | WVE | Wave Life Sciences Ltd. | +1.5% | +0.01% | Add |
| 4 | TYRA | Tyra Biosciences Inc | +1.2% | — | Unchanged |
| 5 | NUVL | Nuvalent Inc-a | +0.6% | +50.83% | Add |
| 6 | EWTX | Edgewise Therapeutics Inc | +0.6% | — | Unchanged |
| 7 | JBIO | Jade Biosciences Inc | +0.5% | +245.57% | Add |
| 8 | SION | Sionna Therapeutics Inc | +0.4% | -5.17% | Trim |
| 9 | SEPN | Septerna Inc | +0.4% | — | Unchanged |
| 10 | TSHA | Taysha Gene Therapies Inc | +0.4% | — | Unchanged |
| 11 | IRON | Disc Medicine Inc | +0.3% | +25.30% | Add |
| 12 | RYTM | Rhythm Pharmaceuticals Inc | +0.2% | +17.35% | Add |
| 13 | PEPG | Pepgen Inc | +0.2% | — | Unchanged |
| 14 | IVVD | Invivyd Inc | +0.2% | — | Unchanged |
| 15 | LBRX | Lb Pharmaceuticals Inc | +0.2% | +24.29% | Add |
| 16 | DSGN | Design Therapeutics Inc | +0.1% | +207.21% | Add |
| 17 | ARTV | Artiva Biotherapeutics Inc | +0.1% | — | Unchanged |
| 18 | SABS | Sab Biotherapeutics Inc | +0.1% | — | Unchanged |
| 19 | ASMB | Assembly Biosciences Inc | 0% | — | Unchanged |
| 20 | CLYM | Climb Bio Inc | 0% | -64.05% | Trim |
| 21 | ACRV | Acrivon Therapeutics Inc | 0% | — | Unchanged |
| 22 | INSP | Inspire Medical Systems Inc | 0% | +23.55% | Add |
| 23 | AVTX | Avalo Therapeutics Inc | 0% | — | Unchanged |
| 24 | ABOS | Acumen Pharmaceuticals Inc | 0% | — | Unchanged |
| 25 | ✓ | Newamsterdam Pharma Company | 0% | — | Unchanged |
| 26 | ✓ | — | — | Unchanged | |
| 27 | WGS | Genedx Holdings CORP | — | — | Unchanged |
| 28 | PGNY | Progyny Inc | — | — | Unchanged |
| 29 | SPRY | Ars Pharmaceuticals Inc | 0% | — | Unchanged |
| 30 | CTNM | Contineum Therapeutics Inc-a | -0.1% | +2.72% | Add |
| 31 | FDMT | 4d Molecular Therapeutics In | -0.1% | +23.89% | Add |
| 32 | MNPR | Monopar Therapeutics Inc | -0.1% | +30.52% | Add |
| 33 | NKTX | Nkarta Inc | -0.1% | — | Unchanged |
| 34 | BLTE | Belite Bio Inc - Adr | -0.1% | -50.57% | Trim |
| 35 | SLDB | Solid Biosciences Inc | -0.1% | — | Unchanged |
| 36 | NAMS | NewAmsterdam Pharma Company N.V. | -0.1% | -5.81% | Trim |
| 37 | HOWL | Werewolf Therapeutics Inc | -0.1% | — | Unchanged |
| 38 | BCAX | Bicara Therapeutics Inc | -0.2% | — | Unchanged |
| 39 | GERN | Geron CORP | -0.2% | +5.62% | Add |
| 40 | PCVX | Vaxcyte Inc | -0.2% | -10.37% | Trim |
| 41 | GHRS | GH Research PLC | -0.4% | — | Unchanged |
| 42 | FULC | Fulcrum Therapeutics Inc | -0.5% | -40.82% | Trim |
| 43 | VOR | Vor Biopharma Inc | -0.5% | +172.66% | Add |
| 44 | MLYS | Mineralys Therapeutics Inc | -0.7% | — | Unchanged |
| 45 | DNTH | Dianthus Therapeutics Inc | -0.7% | -43.78% | Trim |
| 46 | LENZ | Lenz Therapeutics Inc | -1.7% | — | Unchanged |
| 47 | JANX | Janux Therapeutics Inc | -1.8% | — | Unchanged |
| 48 | ACLXGBX | Arcellx Inc | -2.2% | -58.27% | Trim |
| 49 | ASND | Ascendis Pharma A/S | -2.7% | — | Unchanged |
| 50 | ETNBGBP | 89bio Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Ra Capital Management, L.p. reported a total U.S. public equity portfolio value of $11.5B across 71 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ASND, CDTX, RYTM) accounted for 41.4% of total reported equity market value during Q4 2025.
Top New Position Initiated
BCRX
市值: $123.5M
Top Position Liquidated / Trimmed
ETNBGBP
前期市值: $292.4M
During Q4 2025, Ra Capital Management, L.p.'s top holdings by market value included ASND (22.5%)、CDTX (7.6%)、RYTM (7.3%). The largest single position, ASND, represented 22.5% of total portfolio value.
In Q4 2025, Ra Capital Management, L.p. made 61 total portfolio adjustments, initiating 22 new buys, adding to 13 positions, trimming 8 holdings, and fully liquidating 18 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.